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Abstract: Prostate-specific Antigen (PSA) is the biomarker that is used for prostate cancer (PCa) 
detection, although its lack of specificity results in a high rate of false-positives and many 
unnecessary biopsies. Therefore, there is a need for more specific cancer biomarkers for PCa. Recent 
studies have shown that the aberrant glycosylation of proteins is a common feature of the presence 
of cancer. In the case of prostate cancer, there are changes in core-fucose and sialic acids in the glycan 
structure of PSA. In this work, we describe two different strategies to direct the selection of aptamers 
toward the glycans of PSA. From these strategies, we identified two aptamers (PSA-1 and PSAG-1) 
that bind to the glycan structure of PSA with high affinity. Both aptamers were applied in the design 
of electrochemical aptasensors, in sandwich and direct formats, in order to detect the changes in the 
glycosylation of PSA. The sensors responded to different levels of PSA in serum, and they showed 
higher potential to discriminate clinically-meaningful PCa than the ELISA (Enzyme-linked 
immunosorbent assay) test used in hospitals (reducing the number of false positives), although 
validation on more samples is needed. 




Prostate cancer (PCa) is the most frequently diagnosed cancer, and the second most prevalent 
cause of cancer death in men. The approved tests to diagnose prostate cancer are digital rectal exam 
and the analysis of the levels of Prostate-specific Antigen (PSA) in the blood. However, because their 
low sensitivity and specificity, an invasive prostate biopsy is needed to confirm the presence of the 
tumor. PSA is the most prevalently used PCa biomarker in the clinical practice. The test consists in 
the measurement of the PSA levels in serum, with a cut-off of 4 ng/mL. However, this test is not 
specific in the gray zone, between 4 and 10 ng/mL, where the concentration of PSA is not only 
indicative of cancer but also of other benign prostate diseases. This results in a high number of false 
positives and leads to many unnecessary biopsies. Therefore, new tests for PCa diagnosis are needed 
[1,2]. 
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The well-established association between aberrant glycosylation and cancer suggests that the 
analysis of tumor-linked glycan alterations could be a valuable tool for cancer diagnosis [3]. In 
prostate cancer, a variation in the content of the fucose and the sialic acids in the glycan linked to PSA 
was described [4]. The glycosylation profile is currently characterized by long and complicated 
protocols based on final mass spectrometry detection or the use of lectins. For routine analysis, 
however, the development of rapid, direct methods for the detection of aberrant glycosylated forms 
of PSA requires specific receptors with higher affinity than lectins. Aptamers can be tailored to 
specifically recognize the glycan moiety turning into promising synthetic receptors, in order to 
replace the current methods for glycosylation profiling [5]. 
In this work, we present a strategy to select aptamers toward the glycosylation site of the 
glycoprotein PSA. The aptamers were used in the design of electrochemical aptasensors for the 
detection of changes in the glycosylation pattern of PSA associated to PCa (Figure 1). 
 
Figure 1. Overview of the work described in this conference proceeding paper: (A) the selection of 
aptamers directed to the glycan structure of PSA, and (B) the design of aptasensors for prostate cancer 
diagnosis. 
2. Materials and Methods  
2.1. Materials and Apparatus 
A detailed list of the materials and apparatus is available in references [6,7]. 
2.2. SELEX Procedure 
The SELEX (Systematic Evolution of ligands by Exponential Enrichment) procedure is an 
iterative process, and each cycle consists of the following steps: the incubation of an ssDNA library 
with the target (PSA), the separation of the unbound sequences, the elution of the bound ones, the 
amplification of the eluted sequences by PCR (Polymerase chain reaction), and strand separation to 
start a new round of selection (Figure 1A).  
In this work, we used an initial ssDNA library of 80 nucleotides (nt)-length with a 40 nt 
randomized central region, flanked at both ends by two constant sequences of 20 nucleotides each. 
To make the separation and elution steps easier, the protein PSA was immobilized on the surface of 
tosylactivated magnetic particles. In order to direct the selection toward the glycosylation site of the 
protein, we performed two strategies: the first was based on the introduction of counter-selection 
steps with recombinant PSA (rPSA), an unglycosylated form of the protein; and the second was based 
on counter-selection with rPSA and competitive elution with a lectin.  
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The counter-selection step consisted in the incubation of the ssDNA library with rPSA, and after 
the interaction, the unbound sequences were collected and incubated with PSA. The following steps 
of the SELEX were performed in the traditional way. 
The competitive elution with the lectin consisted in the elution of the sequences bound to PSA 
by adding a high concentration of the lectin in solution, which displaced the sequences that bind to 
the lectin-binding site. 
A comprehensive and detailed explanation of the protocols can be found in reference [6,7]. 
2.3. Electrochemical Binding Assays 
The aptamers were screened by affinity assays with electrochemical detection. With this aim, 
PSA was covalently immobilized onto screen-printed gold electrodes. First, a self-assembled 
monolayer (SAM) of a mixture 1:3 11-mercaptoundecanoic acid and 6-mercaptohexanol (both 1 mM) 
in an NaAc buffer (10 mM pH 5.5) was prepared overnight at 4 °C. The carboxylic groups were 
activated with a solution of 100 mM EDC (N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride) and 25 mM NHS (N-hydroxysuccinimide) in water for 30 min, and then PSA was 
covalently immobilized by incubating the electrodes in 50 µg/mL PSA for 30 min. Finally, the 
remaining active groups were blocked with ethanolamine 1 M in PBS (1 × pH 7.4) for 30 min. 
Binding assays were performed by incubating the modified electrode with increasing 
concentrations of the aptamers labelled with fluorescein for 30 min in PBS. After the interaction, the 
conjugate Fab-antifluorescein-peroxidase (Fab-POD: 0.5 U/mL in PBS-0.5% casein) was added for 30 
min. Finally, the electrochemical measurement was carried out with 35 µL TMB-H2O2, and the 
enzymatic product was measured after 30 s by chronoamperometry at −0.2 V for 1 min. The current 
obtained during the last 10 s was averaged and related with the aptamer concentration. 
2.4. Deglycosyation Studies 
The interaction of PSA with specific glycosidase enzymes was performed on screen-printed gold 
electrodes modified with PSA, as indicated above. The incubation order was as follows: 
neuraminidase-A, β-galactosidase, N-acetylhexosaminidase, mannosidase, fucosidase, and 
PNGaseF. The preparation of the enzymes (buffer and concentration) was performed following the 
manufacturer’s protocols. The incubations were performed at 37 °C in a volume of 10 µL in a wet 
atmosphere for 2 h, except for the PNGaseF enzyme, which had an incubation period of 24 h. Then, 
the binding capacity of the aptamers was tested by performing an electrochemical binding assay with 
PSAG-1 or PSA-1 as indicated above [7]. 
2.5. Sandwich Aptasensor 
To fabricate the sensor, the capture biotinylated aptamer (anti-PSA) was immobilized onto 
screen-printed gold electrodes modified with streptavidin. For the PSA analysis, different 
concentrations of PSA prepared in TBS (10 mM Tris-HCl, 150 mM NaCl, 5 mM KCl, 5 mM MgCl2 pH 
7.4) or diluted serum were incubated on the working electrode for 30 min, and then the detection 
aptamer (PSA-1) was added for 30 min. Next, the bound aptamer was labeled with Fab-POD for 30 
min in TBS-0.5% casein. Finally, the electrochemical measurement was carried out as described above 
[6]. 
2.6. Impedimetric Aptasensor 
A dual impedimetric platform for the direct measurement of PSA was developed by 
immobilizing a thiolated aptamer (anti-PSA or PSAG-1) onto nanostructured gold electrodes. Each 
aptamer layer was prepared on gold electrodes modified with 11-amino-1-undecanothiol and 6-
mercapto-1-hexanol, and by attaching gold nanoparticles to the amine group in the SAM. For the PSA 
detection, the sensors were incubated with increasing concentrations of PSA in PBS for 30 min and, 
after the interaction, the impedance was measured in 5 mM Fe[(CN)6]3−/4− at 0.22 V vs. Ag|AgCl, KCl 
(3M)|KNO3 (3M).  
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3. Results and Discussion 
3.1. Selection and Characterization of Aptamers 
To direct the selection of aptamers toward the glycosylation site of the PSA, two counter-
selection steps against the recombinant PSA (rPSA) were introduced into the six-round SELEX. One 
of the obtained aptamers (PSA-1) showed preferential binding for PSA over rPSA, and its affinity and 
selectivity was evaluated in detail. A dissociation constant of 357 ± 42 nM was estimated. However, 
this aptamer also recognized other glycoproteins (Lipocalin-2 or NGAL), meaning that PSA-1 binds 
to the glycan moiety and not to the peptide region of the protein. Consequently, PSA-1 might be a 
good receptor for human glycans [6]. 
In order to refine the selection of the aptamers, obtaining receptors that are able to differentiate 
glycoproteins with similar glycosylation patterns, we proposed a selection based on counter-selection 
steps against rPSA and competitive elution with the lectin PhoSL (specific binder of α1-6 core-fucose). 
After ten rounds of selection, one aptamer (PSAG-1) preferentially bound to PSA with a dissociation 
constant of 34 ± 9 nM. This aptamer showed selectivity against other glycoproteins: NGAL (lipocalin-
2), AFP (α-fetoprotein), ovalbumin and transferrin. This indicates that the molecular interaction of 
PSAG-1 and PSA involved both the glycans and some of the amino acids of the protein [7]. 
3.2. Study of the Binding Site 
To find out which sugars in the glycan structure are involved in the recognition of PSA by both 
of the aptamers, the sugars of PSA immobilized onto the gold electrodes were removed using 
selective glycosidases. After each sugar removal, the binding ability of the aptamers was tested. From 
this study, we observed that PSA-1 and PSAG-1 aptamers have a completely different binding 
pattern. PSA-1 recognizes the external sugars (sialic acid and galactose), while PSAG-1 recognizes 
the innermost sugars [7]. 
3.3. Detection of Glycosylated PSA Using Aptasensors 
We employed the selected aptamers and a previously described aptamer (anti-PSA), which only 
recognizes the peptide moiety [8], for the development of the electrochemical aptasensors. Two 
different formats—sandwich and direct label-free approaches—were designed using gold electrodes as 
support. 
The sandwich aptasensor, using anti-PSA as the capture aptamer and PSA-1 as the detection 
aptamer, has a working range between 0.66 ng/mL and 25 ng/mL in 1:1 diluted serum, and a detection 
limit of 0.66 ng/mL PSA. This sensor has an excellent selectivity against other proteins (rPSA and 
NGAL) and 92 analytes present in biological fluids [6]. 
The direct label-free assay was performed on a dual impedimetric platform with two sensors, 
one with anti-PSA and the other with the PSAG-1 aptamer. Both sensors respond to increasing 
concentrations of PSA in 1:5 diluted serum. The working range of the anti-PSA sensor is between 0.64 
ng/mL and 62.5 ng/mL, and 0.26 ng/mL to 62.5 ng/mL for the PSAG-1 sensor [9]. 
Both aptasensors were applied to the analysis of serum samples from patients with benign or 
malignant prostate pathologies from the clinical analysis laboratory at Hospital de Cabueñes (Gijón, 
Spain). For samples with PSA concentrations in the grey zone or above, the aptasensors provided 
discordant values compared to those obtained by the ELISA, but which were in close agreement with 
the final diagnosis (no prostate cancer). Therefore, the results point to the detection of glycans as an 
alternative for the detection of prostate cancer, with potential to improve the clinical outcomes of the 
current PSA test, reducing the number of unnecessary biopsies [6,9]. 
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